FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Muralidhar Beeram

Research Profile

Disorders

Concepts & Ideas

Chemicals & Drugs

Procedures

Devices

Drug Delivery Systems

Physiology

Drug Interactions

Co-author Network

Publications

TOP 3
Muralidhar Beeram; Howard A Burris; Sandhya R Girish; Scott N Holden; Ian E Krop; Michael W Lu; Wei Yu; Shanu Modi
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
Manish Gupta; Amita Joshi; Barbara Klencke; Patricia M LoRusso; Shanu Modi; Bei Wang; Joo-Hee Yi; Samuel Agresta; Muralidhar Beeram; Howard A Burris; Yu-Waye Chu; Sandhya Girish
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Toshio Shimizu; Leslie Ann Smetzer; Lon S Smith; Anthony W Tolcher; Michael J Wick; Drew W Rasco; Cathy Alvarez; Muralidhar Beeram; Aracely Cavazos; Shelly Gunn; Brianne Kaiser; Gina L Mangold; Theresa A Mays; Kyriakos P Papadopoulos; Amita Patnaik
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Muralidhar Beeram (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Muralidhar Beeram; Howard A Burris; Sandhya R Girish; Scott N Holden; Ian E Krop; Michael W Lu; Wei Yu; Shanu Modi
A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.
Cancer 2012;118(23):5733-40.
2012: Manish Gupta; Amita Joshi; Barbara Klencke; Patricia M LoRusso; Shanu Modi; Bei Wang; Joo-Hee Yi; Samuel Agresta; Muralidhar Beeram; Howard A Burris; Yu-Waye Chu; Sandhya Girish
Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.
Journal of clinical pharmacology 2012;52(5):691-703.
2012: Toshio Shimizu; Leslie Ann Smetzer; Lon S Smith; Anthony W Tolcher; Michael J Wick; Drew W Rasco; Cathy Alvarez; Muralidhar Beeram; Aracely Cavazos; Shelly Gunn; Brianne Kaiser; Gina L Mangold; Theresa A Mays; Kyriakos P Papadopoulos; Amita Patnaik
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(8):2316-25.
2011: Muhammad Wasif Saif; John Sarantopoulos; Chris H Takimoto; Anthony W Tolcher; Amita Patnaik; Muralidhar Beeram
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2011;68(6):1565-73.
2011: Chee M Ng; Amita Patnaik; Muralidhar Beeram; C C Lin; Chris H Takimoto
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.
Cancer chemotherapy and pharmacology 2011;67(5):985-94.
2010: Ian Krop; Muralidhar Beeram; Shanu Modi; Suzanne F Jones; Scott N Holden; Wei Yu; Sandhya Girish; Jay Tibbitts; Joo-Hee Yi; Mark X Sliwkowski; Fred Jacobson; Stuart G Lutzker; Howard A Burris
Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(16):2698-704.
2009: Chia-Chi Lin; Muralidhar Beeram; Eric K Rowinsky; Chris H Takimoto; Chee M Ng; Charles E Geyer; Louis J Denis; Johann S de Bono; Desiree Hao; Anthony W Tolcher; Sun-Young Rha; Jacques Jolivet; Amita Patnaik
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Cancer chemotherapy and pharmacology 2009;65(1):167-75.
2009: Catalin Mita; Louis J Denis; Eric K Rowinsky; Johann S Debono; Andrew D Goetz; Leonel Ochoa; Bahram Forouzesh; Muralidhar Beeram; Amita Patnaik; Kathleen Molpus; Dorothée Semiond; Michèle Besenval; Anthony W Tolcher
Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(2):723-30.
2008: Kyriakos P Papadopoulos; SANJAY GOEL; Muralidhar Beeram; Alvin Wong; Kavita Desai; Missak Haigentz; María L Milián; Sridhar Mani; Anthony W Tolcher; Alshad S Lalani; John Sarantopoulos
A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):7110-5.
2008: David F McDermott; Jeffrey A Sosman; Rene Gonzalez; F Stephen Hodi; Gerald P Linette; Jon Richards; James Jakub; Muralidhar Beeram; Stefano Tarantolo; Sanjiv Agarwala; Gary Frenette; Igor Puzanov; Lee Cranmer; Karl Lewis; John Kirkwood; J Michael White; Chenghua Xia; Kiran Patel; Evan M Hersh
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2178-85.
2007: Catalin Mita; Anthony J Olszanski; Richard C Walovitch; Raymond P Perez; Kathleen MacKay; David P Tuck; Cecilia Simmons; Susan Hammond; Monica Mita; Muralidhar Beeram; Anne J Stone; Eric K Rowinsky; Lionel D Lewis
Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3293-301.
2007: Chris H Takimoto; Lisa A Hammond-Thelin; Jane E Latz; Leonardo Forero; Muralidhar Beeram; Bahram Forouzesh; Johann S de Bono; Anthony W Tolcher; Amita Patnaik; Pamela Monroe; Leslie Wood; Karen B Schneck; Romnee Clark; Eric K Rowinsky
Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(9):2675-83.
2007: Monica Mita; Eric K Rowinsky; Leonardo Forero; S Gail Eckhart; Elzbieta Izbicka; Geoffrey R Weiss; Muralidhar Beeram; Catalin Mita; Johann S de Bono; Anthony W Tolcher; Lisa A Hammond; Paul Simmons; Kristin Berg; Chris H Takimoto; Amita Patnaik
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Cancer chemotherapy and pharmacology 2007;59(2):165-74.
2007: Eric K Rowinsky; Muralidhar Beeram; Lisa A Hammond; Garry Schwartz; Johann S de Bono; Bahram Forouzesh; Quincy Chu; Jane E Latz; Shengyan Hong; William John; Binh Nguyen
A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(2 Pt 1):532-9.
2006: Amita Patnaik; Debra Wood; Anthony W Tolcher; Marta Hamilton; Jeffrey I Kreisberg; Lisa A Hammond; Garry Schwartz; Muralidhar Beeram; Manuel Hidalgo; Monica Mita; Julie Wolf; Paul Nadler; Eric K Rowinsky
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(24):7406-13.
2005: Muralidhar Beeram; Amita Patnaik; Eric K Rowinsky
Raf: a strategic target for therapeutic development against cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6771-90.
2003: Muralidhar Beeram; Amita Patnaik; Eric K Rowinsky
Regulation of c-Raf-1: therapeutic implications.
Clinical advances in hematology & oncology : H&O 2003;1(8):476-81.
2002: Muralidhar Beeram; Amita Patnaik
Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics.
Hematology/oncology clinics of North America 2002;16(5):1089-100.